A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

Trial Details

NCT ID

NCT06280105

Phase

PHASE2

Sponsor

Meng Chao Hepatobiliary Hospital of Fujian Medical University

Status

RECRUITING

Cancer Type

Liver Cancer

Interventions

• Cadonilimab+regorafenib

Locations (sample)

• Fuzhou, Fujian, China|26.06139,119.30611

Key Eligibility Criteria

• Sign a written informed consent form before enrollment;
• Age \>18 years old, both sex;
• Histological or pathological confirmed intermediate or advanced hepatocellular carcinoma, or patients with cirrhosis who meet the clinical diagnost…
• Have progressed on the combination treatment of camrelizumab and apatinib for HCC

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.